AR065072A2 - Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo - Google Patents

Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo

Info

Publication number
AR065072A2
AR065072A2 ARP080100352A ARP080100352A AR065072A2 AR 065072 A2 AR065072 A2 AR 065072A2 AR P080100352 A ARP080100352 A AR P080100352A AR P080100352 A ARP080100352 A AR P080100352A AR 065072 A2 AR065072 A2 AR 065072A2
Authority
AR
Argentina
Prior art keywords
weight
active compound
release
controlled
drug
Prior art date
Application number
ARP080100352A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR065072A2 publication Critical patent/AR065072A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo, que comprende: a) 50-95% en peso de un nucleo, comprendiendo dicho nucleo del 70-95% en peso del compuesto activo, seleccionado del ácido 1-ciclopropil-7-[(S,S)-2,8- diazabiciclo[4.3.0]non-8-iI)-6-fluor-1,4-dihidro-8-metoxi-4-oxo-3-quinoloncarboxílico o sales farmacéuticamente aceptables y/o hidratos del mismo, y/o 0,5%-30% en peso de un aglutinante; y b) 5-50% en peso de un revestimiento de difusion que reviste dicho nucleo, comprendiendo dicho revestimiento de difusion 40-90% en peso de una película anterior, 0-50% en peso de un formador de poros y 5-50% en peso de un plastificante, en donde dicha formulacion medicamentosa tiene una liberacion promedio del compuesto activo de entre 80% en 2 horas y 80% en 16 horas y una liberacion inicial que es menor del 60% del compuesto activo en la primera hora de liberacion. Reivindicacion 4: La formulacion medicamentosa segun la reivindicacion 1, caracterizada porque dicha formulacion medicamentosa es un sistema de liberacion medicamentosa osmotica.
ARP080100352A 1997-09-25 2008-01-29 Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo AR065072A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19742243 1997-09-25

Publications (1)

Publication Number Publication Date
AR065072A2 true AR065072A2 (es) 2009-05-13

Family

ID=7843534

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980104797A AR013967A1 (es) 1997-09-25 1998-09-25 UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
ARP080100352A AR065072A2 (es) 1997-09-25 2008-01-29 Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo
ARP080100353A AR065073A2 (es) 1997-09-25 2008-01-29 Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980104797A AR013967A1 (es) 1997-09-25 1998-09-25 UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080100353A AR065073A2 (es) 1997-09-25 2008-01-29 Una formulacion medicamentosa de sistema de matriz que tiene liberacion controlada de un compuesto activo

Country Status (37)

Country Link
US (1) US6270799B1 (es)
EP (1) EP1017392B1 (es)
JP (2) JP2001517625A (es)
KR (1) KR100531065B1 (es)
CN (3) CN1895233A (es)
AR (3) AR013967A1 (es)
AT (1) ATE220547T1 (es)
AU (1) AU731693B2 (es)
BG (1) BG64745B1 (es)
BR (1) BR9812553B1 (es)
CA (1) CA2304135C (es)
CO (1) CO5011082A1 (es)
CZ (1) CZ293062B6 (es)
DE (1) DE59804823D1 (es)
DK (1) DK1017392T3 (es)
ES (1) ES2179533T3 (es)
GT (1) GT199800152A (es)
HK (1) HK1032010A1 (es)
HN (1) HN1998000144A (es)
HU (1) HU226583B1 (es)
ID (1) ID24259A (es)
IL (1) IL134591A0 (es)
MY (1) MY129437A (es)
NO (1) NO327492B1 (es)
NZ (1) NZ503538A (es)
PE (1) PE20000224A1 (es)
PL (1) PL192273B1 (es)
PT (1) PT1017392E (es)
SI (1) SI1017392T1 (es)
SK (1) SK283462B6 (es)
SV (1) SV1998000119A (es)
TR (1) TR200000752T2 (es)
TW (1) TW523412B (es)
UA (1) UA66812C2 (es)
UY (1) UY25192A1 (es)
WO (1) WO1999015172A1 (es)
ZA (1) ZA988718B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
AU2002236132A1 (en) * 2002-03-05 2003-09-16 Ranbaxy Laboratories Limited Modified release oral pharmaceutical composition
ITMI20020515A1 (it) * 2002-03-12 2003-09-12 Jagotec Ag Sistema per il rilasco controllato di uno o piu' principi attivi
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
PL1691787T3 (pl) * 2003-12-04 2008-11-28 Pfizer Prod Inc Sposób wytwarzania farmaceutycznych systemów wielocząstkowych
GB2409204A (en) * 2003-12-19 2005-06-22 Reckitt Benckiser Nv Plasticized thermoplastic polymer
PT1868581E (pt) * 2005-04-11 2012-06-22 Abbott Lab Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis
CN1762357B (zh) * 2005-09-21 2010-12-08 深圳市天一时科技开发有限公司 一种莫西沙星口服药物制剂及其制备方法
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
EP2837376A3 (de) 2008-12-08 2015-03-25 ratiopharm GmbH Kompaktiertes Moxifloxacin
ITTO20110705A1 (it) * 2011-07-29 2013-01-30 Italiana Sint Spa Procedimento di preparazione della moxifloxacina cloridrato e relativi intermedi
KR20200077712A (ko) 2018-12-21 2020-07-01 한미약품 주식회사 목시플록사신 고형 제제 및 이의 제조방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485770A (en) 1967-03-02 1969-12-23 Atlantic Richfield Co Olefin polymerization catalyst based on aluminum pyrolate
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4036227A (en) 1973-04-25 1977-07-19 Alza Corporation Osmotic releasing device having a plurality of release rate patterns
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US3977404A (en) 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
CH668187A5 (de) 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
DE3868077D1 (de) 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
SE8704097D0 (sv) * 1987-10-22 1987-10-22 Astra Ab Oral formulation of buspirone and salts thereof
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
TW209865B (es) * 1992-01-10 1993-07-21 Bayer Ag
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5520920A (en) 1992-08-28 1996-05-28 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
JP3220331B2 (ja) 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5473103A (en) 1993-12-16 1995-12-05 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Biopolymers derived from hydrolyzable diacid fats
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use

Also Published As

Publication number Publication date
DE59804823D1 (de) 2002-08-22
PL192273B1 (pl) 2006-09-29
CO5011082A1 (es) 2001-02-28
HU226583B1 (hu) 2009-04-28
UY25192A1 (es) 2001-08-27
AU731693B2 (en) 2001-04-05
SK283462B6 (sk) 2003-08-05
CZ20001076A3 (cs) 2000-07-12
NO20001375L (no) 2000-03-16
CA2304135A1 (en) 1999-04-01
ZA988718B (en) 1999-04-01
HUP0003840A2 (hu) 2001-04-28
CN1178659C (zh) 2004-12-08
BR9812553A (pt) 2000-07-25
WO1999015172A1 (de) 1999-04-01
AU9348498A (en) 1999-04-12
ATE220547T1 (de) 2002-08-15
JP2010163455A (ja) 2010-07-29
NO20001375D0 (no) 2000-03-16
CN1271281A (zh) 2000-10-25
PT1017392E (pt) 2002-10-31
CZ293062B6 (cs) 2004-01-14
TR200000752T2 (tr) 2000-09-21
KR100531065B1 (ko) 2005-11-28
BG64745B1 (bg) 2006-02-28
GT199800152A (es) 2000-03-17
US6270799B1 (en) 2001-08-07
SI1017392T1 (en) 2002-12-31
DK1017392T3 (da) 2002-10-21
ES2179533T3 (es) 2003-01-16
BR9812553B1 (pt) 2010-06-01
CA2304135C (en) 2009-01-06
JP2001517625A (ja) 2001-10-09
SV1998000119A (es) 1999-03-02
CN1623533A (zh) 2005-06-08
MY129437A (en) 2007-04-30
PL339349A1 (en) 2000-12-18
KR20010024269A (ko) 2001-03-26
EP1017392B1 (de) 2002-07-17
BG104256A (en) 2000-12-29
HK1032010A1 (en) 2001-07-06
IL134591A0 (en) 2001-04-30
NO327492B1 (no) 2009-07-20
AR013967A1 (es) 2001-01-31
AR065073A2 (es) 2009-05-13
EP1017392A1 (de) 2000-07-12
TW523412B (en) 2003-03-11
SK4032000A3 (en) 2000-09-12
CN1895233A (zh) 2007-01-17
ID24259A (id) 2000-07-13
HUP0003840A3 (en) 2006-06-28
NZ503538A (en) 2001-03-30
HN1998000144A (es) 1999-06-02
PE20000224A1 (es) 2000-05-11
UA66812C2 (uk) 2004-06-15

Similar Documents

Publication Publication Date Title
AR065072A2 (es) Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo
ES2135443T3 (es) Vehiculo mejorado para la administracion oral de omeprazol.
ATE53176T1 (de) Pharmazeutische zusammensetzung mit verzoegerter abgabe.
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
ATE324872T1 (de) Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern
DE69100991T2 (de) Pharmazeutische formulierungen.
BR0015567A (pt) Compostos de ácido fenoxicarboxìlico e composições para liberar agentes ativos
DE69909316D1 (de) Pharmazeutische formulierung mit omeprazol
ATE232091T1 (de) Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung von reversiblen protonpumpen-inhibitoren
CA2307018A1 (en) Osmotic medicament releasing system
CN101371845B (zh) 一种用于治疗口腔溃疡药物组合物
HRP20040323C1 (hr) Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance
CL2004001182A1 (es) Composicion farmaceutica que comprende a una microparticula de liberacion sostenida la que contiene a un derivado de 1,2 benzazol; procedimiento de preparacion de la microparticula; util como broncodilatador, antipsicoticos y en otros problemas del s
BR0112532A (pt) Composição farmacêutica oral, sistema galênico e uso da composição
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
ES2168043A1 (es) Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
DE69133623D1 (de) Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung
ATE43497T1 (de) Pharmazeutische formulierung mit gesteuerter absorption.
IT1257793B (it) Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
HU9301672D0 (en) Method for manufacturing solid dosing forms of medicaments with controlled releasing of active agents
JP2001517625A5 (es)
ATE203906T1 (de) Zubereitung zur perkutanen verabreichung enthaltend 6-amino-5-chloro-1-isopropyl-2-(4- methyl-1-piperazinyl)benzimidazol
ATE213933T1 (de) Orale zubereitung, enthaltend in einer in wässrigem medium quellbaren matrix wenigstens einen pharmazeutischen wirkstoff
AU2002328873A1 (en) Dosage forms comprising particles containing active ingredient for application on the skin or mucous membrane

Legal Events

Date Code Title Description
FG Grant, registration